Debra Zack, Exagen Inc.'s Chief Medical Officer, recently acquired 37,500 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on February 23, 2021. Zack now owns 37,500 shares of the company. Zack operates out of Vista, CA. Some additional info was provided as follows:
Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of March 1, 2020, subject to the Reporting Person's continued service through the applicable vesting date. In addition, the award may become fully vested upon a qualifying termination of employment in connection with a change in control.
Represents 37,500 shares of restricted stock units.
The option is exercisable as it vests. 25% of the shares subject to the option vest on February 23, 2022, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. In addition, the stock option may become fully vested upon a qualifying termination of employment in connection with a change in control.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Exagen Inc. makes a similar move, sign up!